SG11201809856SA - Combination of pure 5-ht6 receptor antagonists with acetylcholinesterase inhibitors - Google Patents
Combination of pure 5-ht6 receptor antagonists with acetylcholinesterase inhibitorsInfo
- Publication number
- SG11201809856SA SG11201809856SA SG11201809856SA SG11201809856SA SG11201809856SA SG 11201809856S A SG11201809856S A SG 11201809856SA SG 11201809856S A SG11201809856S A SG 11201809856SA SG 11201809856S A SG11201809856S A SG 11201809856SA SG 11201809856S A SG11201809856S A SG 11201809856SA
- Authority
- SG
- Singapore
- Prior art keywords
- road
- telangana
- hyderabad
- serene
- avenue
- Prior art date
Links
- 239000000544 cholinesterase inhibitor Substances 0.000 title abstract 3
- 239000002464 receptor antagonist Substances 0.000 title abstract 3
- 229940044551 receptor antagonist Drugs 0.000 title abstract 3
- 108091005435 5-HT6 receptors Proteins 0.000 title abstract 2
- 239000003795 chemical substances by application Substances 0.000 abstract 2
- 229940125904 compound 1 Drugs 0.000 abstract 2
- 229940125782 compound 2 Drugs 0.000 abstract 2
- 229940126214 compound 3 Drugs 0.000 abstract 2
- ADEBPBSSDYVVLD-UHFFFAOYSA-N donepezil Chemical compound O=C1C=2C=C(OC)C(OC)=CC=2CC1CC(CC1)CCN1CC1=CC=CC=C1 ADEBPBSSDYVVLD-UHFFFAOYSA-N 0.000 abstract 2
- 101100075747 Drosophila melanogaster Lztr1 gene Proteins 0.000 abstract 1
- 208000010877 cognitive disease Diseases 0.000 abstract 1
- 229960003530 donepezil Drugs 0.000 abstract 1
- 230000008520 organization Effects 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- 102220240796 rs553605556 Human genes 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/28—Compounds containing heavy metals
- A61K31/305—Mercury compounds
- A61K31/31—Mercury compounds containing nitrogen
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
- A61K31/27—Esters, e.g. nitroglycerine, selenocyanates of carbamic or thiocarbamic acids, meprobamate, carbachol, neostigmine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
Landscapes
- Health & Medical Sciences (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical & Material Sciences (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Psychiatry (AREA)
- Hospice & Palliative Care (AREA)
- Emergency Medicine (AREA)
- Psychology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Steroid Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| IN201641017205 | 2016-05-18 | ||
| PCT/IB2016/054673 WO2017199071A1 (en) | 2016-05-18 | 2016-08-03 | Combination of pure 5-ht6 receptor antagonists with acetylcholinesterase inhibitors |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| SG11201809856SA true SG11201809856SA (en) | 2018-12-28 |
Family
ID=56940098
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SG11201809856SA SG11201809856SA (en) | 2016-05-18 | 2016-08-03 | Combination of pure 5-ht6 receptor antagonists with acetylcholinesterase inhibitors |
Country Status (28)
| Country | Link |
|---|---|
| US (1) | US11458135B2 (sl) |
| EP (1) | EP3484467B1 (sl) |
| JP (1) | JP6606299B2 (sl) |
| KR (1) | KR102015484B1 (sl) |
| CN (2) | CN114642667A (sl) |
| AU (1) | AU2016407427B2 (sl) |
| BR (1) | BR112018073419A2 (sl) |
| CA (1) | CA3023819C (sl) |
| CY (1) | CY1123013T1 (sl) |
| DK (1) | DK3484467T3 (sl) |
| EA (1) | EA036347B1 (sl) |
| ES (1) | ES2796181T3 (sl) |
| HR (1) | HRP20200872T1 (sl) |
| HU (1) | HUE050819T2 (sl) |
| IL (1) | IL262921B (sl) |
| LT (1) | LT3484467T (sl) |
| MA (1) | MA45639B1 (sl) |
| MD (1) | MD3484467T2 (sl) |
| ME (1) | ME03731B (sl) |
| MX (1) | MX2018014185A (sl) |
| NZ (1) | NZ748280A (sl) |
| PL (1) | PL3484467T3 (sl) |
| PT (1) | PT3484467T (sl) |
| RS (1) | RS60422B1 (sl) |
| SG (1) | SG11201809856SA (sl) |
| SI (1) | SI3484467T1 (sl) |
| WO (1) | WO2017199071A1 (sl) |
| ZA (1) | ZA201807468B (sl) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN111084768A (zh) * | 2018-10-24 | 2020-05-01 | 中国科学院昆明动物研究所 | 吉非罗齐及其衍生物用于治疗和/或预防神经退行性疾病的用途 |
| CN111084776A (zh) * | 2018-10-24 | 2020-05-01 | 中国科学院昆明动物研究所 | 匹立尼酸及其衍生物用于治疗和/或预防神经退行性疾病的用途 |
| IL293416A (en) * | 2019-12-02 | 2022-07-01 | Suven Life Sciences Ltd | Treatment of behavioral and psychological symptoms in demented patients |
| WO2021111320A1 (en) | 2019-12-02 | 2021-06-10 | Suven Life Sciences Limited | Methods for treating behavioral and psychological symptoms in patients with dementia |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| PT1581492E (pt) * | 2002-11-28 | 2008-09-19 | Suven Life Sciences Ltd | Indoles n-arilsulfonil-3-substituídos possuindo afinidade de receptor de serotonina, processo para a sua preparação e composição farmacêutica contendo os mesmos |
| PE20071143A1 (es) | 2006-01-13 | 2008-01-20 | Wyeth Corp | Composicion farmaceutica que comprende un inhibidor de acetilcolinesterasa y un antagonista 5-hidroxitriptamina-6 |
| CN101500611A (zh) * | 2006-06-23 | 2009-08-05 | 埃斯蒂维实验室股份有限公司 | 胆碱脂酶抑制剂与具有5-ht6受体亲和力的化合物的组合 |
| AR061637A1 (es) | 2006-06-26 | 2008-09-10 | Epix Delaware Inc | Composiciones y metodos de tratamiento de trastornos del snc |
| JO3459B1 (ar) | 2012-09-09 | 2020-07-05 | H Lundbeck As | تركيبات صيدلانية لعلاج مرض الزهايمر |
| JP6151453B2 (ja) | 2013-12-02 | 2017-06-21 | スヴェン・ライフ・サイエンシズ・リミテッド | １−［（２−ブロモフェニル）スルホニル］−５−メトキシ−３−［（４−メチル−１−ピペラジニル）メチル］−１ｈ−インドールジメシラート一水和物の大規模合成法 |
-
2016
- 2016-08-03 PT PT167666221T patent/PT3484467T/pt unknown
- 2016-08-03 DK DK16766622.1T patent/DK3484467T3/da active
- 2016-08-03 MX MX2018014185A patent/MX2018014185A/es unknown
- 2016-08-03 WO PCT/IB2016/054673 patent/WO2017199071A1/en unknown
- 2016-08-03 MA MA45639A patent/MA45639B1/fr unknown
- 2016-08-03 CN CN202210321209.2A patent/CN114642667A/zh active Pending
- 2016-08-03 US US16/099,161 patent/US11458135B2/en active Active
- 2016-08-03 JP JP2018559336A patent/JP6606299B2/ja active Active
- 2016-08-03 ES ES16766622T patent/ES2796181T3/es active Active
- 2016-08-03 KR KR1020187035983A patent/KR102015484B1/ko active IP Right Grant
- 2016-08-03 CA CA3023819A patent/CA3023819C/en active Active
- 2016-08-03 SI SI201630791T patent/SI3484467T1/sl unknown
- 2016-08-03 AU AU2016407427A patent/AU2016407427B2/en active Active
- 2016-08-03 RS RS20200635A patent/RS60422B1/sr unknown
- 2016-08-03 NZ NZ748280A patent/NZ748280A/en unknown
- 2016-08-03 MD MDE20190594T patent/MD3484467T2/ro unknown
- 2016-08-03 LT LTEP16766622.1T patent/LT3484467T/lt unknown
- 2016-08-03 PL PL16766622T patent/PL3484467T3/pl unknown
- 2016-08-03 SG SG11201809856SA patent/SG11201809856SA/en unknown
- 2016-08-03 BR BR112018073419-5A patent/BR112018073419A2/pt not_active Application Discontinuation
- 2016-08-03 ME MEP-2020-109A patent/ME03731B/me unknown
- 2016-08-03 HU HUE16766622A patent/HUE050819T2/hu unknown
- 2016-08-03 EP EP16766622.1A patent/EP3484467B1/en active Active
- 2016-08-03 CN CN201680085574.0A patent/CN109069468A/zh active Pending
- 2016-08-03 EA EA201892529A patent/EA036347B1/ru unknown
-
2018
- 2018-11-07 ZA ZA2018/07468A patent/ZA201807468B/en unknown
- 2018-11-11 IL IL262921A patent/IL262921B/en active IP Right Grant
-
2020
- 2020-05-29 CY CY20201100489T patent/CY1123013T1/el unknown
- 2020-06-02 HR HRP20200872TT patent/HRP20200872T1/hr unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| SG11201810423XA (en) | Pd-1 / pd-l1 inhibitors for cancer treatment | |
| SG11201901525XA (en) | Muscarinic m1 receptor positive allosteric modulators | |
| SG11201803920TA (en) | Compounds and compositions useful for treating disorders related to ntrk | |
| SG11201805300QA (en) | Heterocyclic compounds as immunomodulators | |
| SG11201811414TA (en) | Heterocyclic compounds as immunomodulators | |
| SG11201804152RA (en) | Heterocyclic compounds as immunomodulators | |
| SG11201810628XA (en) | Nasal pharmaceutical compositions with a porous excipient | |
| SG11201809559UA (en) | Substituted pyridines as inhibitors of dnmt1 | |
| SG11201907544VA (en) | Jak inhibitors containing a 4-membered heterocyclic amide | |
| SG11201808566WA (en) | Polymorphic form of n-{6-(2-hydroxypropan-2-yl)-2-[2-(methylsulphonyl)ethyl]-2h-indazol-5-yl}-6-(trifluoromethyl)pyridine-2-carboxamide | |
| SG11201810280YA (en) | Spiro-lactam nmda receptor modulators and uses thereof | |
| SG11201408251SA (en) | A pharmaceutical composition containing nicotinic acid and/or nicotinamide and/or tryptophan for positively influencing the intestinal microbiota | |
| SG11201408237YA (en) | Compound as wnt signaling inhibitor, composition, and use thereof | |
| SG11201907804QA (en) | Pharmaceutical composition comprising selexipag | |
| SG11201906436VA (en) | Novel heterocyclic compound, its preparation method, and pharmaceutical composition comprising the same | |
| SG11201809856SA (en) | Combination of pure 5-ht6 receptor antagonists with acetylcholinesterase inhibitors | |
| SG11201408750VA (en) | NOVEL FUSED PYRIDINE DERIVATIVES USEFUL AS c-MET TYROSINE KINASE INHIBITORS | |
| SG11201810389XA (en) | New antibacterial compounds | |
| SG11201407402TA (en) | Carbazole-containing sulfonamides as cryptochrome modulators | |
| SG11201901438VA (en) | Solid forms of cenicriviroc mesylate and processes of making solid forms of cenicriviroc mesylate | |
| SG11201908114UA (en) | Pyrimidopyrimidinones useful as wee-1 kinase inhibitors | |
| SG11201901995TA (en) | Crystalline and salt forms of ppar agonist compounds | |
| SG11201909735YA (en) | Therapeutic compounds and compositions, and methods of use thereof | |
| SG11201900633XA (en) | Piperidine cxcr7 receptor modulators | |
| SG11201901850XA (en) | Dopamine-b-hydroxylase inhibitors |